About Heron therapeutics, inc.
Heron Therapeutics, Inc. is a pharmaceutical company that is dedicated to improving the lives of patients through innovative and effective therapies. The company's mission is to advance the therapeutic standard of care for patients by developing and delivering best-in-class medicines that matter.
Heron Therapeutics was founded in 1983 and has since become a leader in the development of novel treatments for pain management, cancer supportive care, and other serious medical conditions. The company's portfolio includes several FDA-approved products, including SUSTOL® (granisetron) extended-release injection for the prevention of chemotherapy-induced nausea and vomiting (CINV), CINVANTI® (aprepitant) injectable emulsion for the prevention of acute and delayed CINV, ZYNRELEF® (bupivacaine and meloxicam) extended-release solution for postoperative pain relief, among others.
One of Heron's most significant achievements has been its development of SUSTOL®, which is designed to provide long-lasting protection against CINV. This condition can be debilitating for cancer patients undergoing chemotherapy treatment, causing nausea and vomiting that can last for days or even weeks after treatment. SUSTOL® offers an extended release formulation that provides up to five days of protection against CINV with just one injection.
Another key product in Heron's portfolio is ZYNRELEF®, which was approved by the FDA in 2021 as a new option for postoperative pain relief following surgery. ZYNRELEF® combines two well-established drugs - bupivacaine, a local anesthetic commonly used during surgery; and meloxicam, a nonsteroidal anti-inflammatory drug - into one extended-release solution that provides up to 72 hours of pain relief after surgery.
In addition to its existing products, Heron Therapeutics has several promising therapies in development across multiple therapeutic areas. These include HTX-011, an investigational combination drug therapy designed to provide long-lasting pain relief after surgery; HTX-019, an investigational therapy being developed as an alternative to opioids for postoperative pain management; among others.
Heron Therapeutics' commitment to innovation extends beyond its product pipeline - it also invests heavily in research partnerships with leading academic institutions around the world. These collaborations help ensure that Heron remains at the forefront of scientific discovery while also providing opportunities for researchers outside the company to contribute their expertise towards developing new treatments.
Overall, Heron Therapeutics' dedication towards advancing patient care through innovative therapies makes it a standout player within the pharmaceutical industry. With its strong track record of success thus far coupled with promising developments on horizon such as HTX-011 & HTX-019 , it seems likely that this company will continue making significant contributions towards improving healthcare outcomes worldwide over time!